Literature DB >> 11238607

Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells.

B Ludewig1, K McCoy, M Pericin, A F Ochsenbein, T Dumrese, B Odermatt, R E Toes, C J Melief, H Hengartner, R M Zinkernagel.   

Abstract

This study evaluated to what extent presentation of exogenously acquired self-Ags via MHC class I molecules on DC might contribute to the activation of self-reactive CTL and subsequent development of autoimmune disease. We show here by using the rat insulin promotor lymphocytic choriomeningitis virus glycoprotein model of autoimmune diabetes that the activation of self-reactive CTL by DC after uptake of exogenous Ag is very limited, first by the short half-life of MHC class I-associated peptides on DC in vitro and in vivo, and second by the rather inefficient MHC class I presentation of cell-associated self-Ags by DC. These two mechanisms are probably crucial in establishing high thresholds for the induction of self-reactive CTL that prevent autoimmune sequelae after release of sequestered and previously immunologically ignored tissue Ags.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238607     DOI: 10.4049/jimmunol.166.6.3678

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

Review 1.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

2.  Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.

Authors:  Hong Shen; Anne L Ackerman; Virginia Cody; Alessandra Giodini; Ella R Hinson; Peter Cresswell; Richard L Edelson; W Mark Saltzman; Douglas J Hanlon
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

3.  A melanoma multiepitope polypeptide induces specific CD8+ T-cell response.

Authors:  Adva Levy; Jacob Pitcovski; Shoshana Frankenburg; Orit Elias; Yael Altuvia; Hanna Margalit; Tamar Peretz; Jacob Golenser; Michal Lotem
Journal:  Cell Immunol       Date:  2008-02-13       Impact factor: 4.868

4.  Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

Authors:  Katelyn T Byrne; Peisheng Zhang; Shannon M Steinberg; Mary Jo Turk
Journal:  J Immunol       Date:  2014-01-08       Impact factor: 5.422

5.  Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.

Authors:  Michal Lotem; Yangbing Zhao; John Riley; Patrick Hwu; Richard A Morgan; Steven A Rosenberg; Maria R Parkhurst
Journal:  J Immunother       Date:  2006 Nov-Dec       Impact factor: 4.456

6.  Latent, Immunosuppressive Nature of Poly(lactic-co-glycolic acid) Microparticles.

Authors:  Riley P Allen; Amir Bolandparvaz; Jeffrey A Ma; Vishal A Manickam; Jamal S Lewis
Journal:  ACS Biomater Sci Eng       Date:  2018-02-03

Review 7.  Intratumoral immunotherapy: using the tumour against itself.

Authors:  Marka R Crittenden; Uma Thanarajasingam; Richard G Vile; Michael J Gough
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

Review 8.  DC-based cancer vaccines.

Authors:  Eli Gilboa
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Multigene RNA vector based on coronavirus transcription.

Authors:  Volker Thiel; Nadja Karl; Barbara Schelle; Petra Disterer; Ingo Klagge; Stuart G Siddell
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity.

Authors:  Vincenzo Russo; Arcadi Cipponi; Laura Raccosta; Cristina Rainelli; Raffaella Fontana; Daniela Maggioni; Francesca Lunghi; Sylvain Mukenge; Fabio Ciceri; Marco Bregni; Claudio Bordignon; Catia Traversari
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.